Polypharmacy in children and adolescents initiating antipsychotic drug in 2008–2016: a nationwide register study

References

• Kalverdijk LJ, Bachmann CJ, Aagaard L, et al. A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012. Child Adolesc Psychiatry Ment Health. 2017;11:55–51.
   PubMed Web of Science ®Google Scholar
• Schroder C, Dorks M, Kollhorst B, et al. Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011. Eur Child Adolesc Psychiatry. 2017;26(4):413–420.
   PubMed Web of Science ®Google Scholar
• Varimo E, Saastamoinen LK, Ratto H, et al. New users of antipsychotics among children and adolescents in 2008-2017: a nationwide register study. Front Psychiatry. 2020;11:316.
   PubMed Web of Science ®Google Scholar
• Chen W, Cepoiu-Martin M, Stang A, et al. Antipsychotic prescribing and safety monitoring practices in children and youth: a Population-Based study in Alberta, Canada. Clin Drug Investig. 2018;38(5):449–455.
   PubMed Web of Science ®Google Scholar
• Dinnissen M, Dietrich A, van der Molen JH, et al. Prescribing antipsychotics in child and adolescent psychiatry: guideline adherence. Eur Child Adolesc Psychiatry. 2020;29(12):1717–1727.
   PubMed Web of Science ®Google Scholar
• Nesvåg R, Hartz I, Bramness JG, et al. Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. Eur Neuropsychopharmacol. 2016;26(9):1412–1418.
   PubMed Web of Science ®Google Scholar
• Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015;72(9):867–874.
   PubMed Web of Science ®Google Scholar
• Vanbronkhorst SB, Roberts DE, Edwards EM, et al. Diagnosis and use of psychotherapy among children and adolescents prescribed antipsychotics. J Psychiatr Pract. 2018;24(5):323–330.
   PubMed Web of Science ®Google Scholar
• Rettew DC, Greenblatt J, Kamon J, et al. Antipsychotic medication prescribing in children enrolled in medicaid. Pediatrics. 2015;135(4):658–665.
   PubMed Web of Science ®Google Scholar
• Chow ES, Zangeneh-Kazemi A, Akintan O, et al. Prescribing practices of quetiapine for insomnia at a tertiary care inpatient child and adolescent psychiatry unit: a continuous quality improvement project. J Can Acad Child Adolesc Psychiatry. 2017;26(2):98–103.
   PubMed Web of Science ®Google Scholar
• Saldaña SN, Keeshin BR, Wehry AM, et al. Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization. Pharmacotherapy 2014;34(8):836–844.
   PubMed Web of Science ®Google Scholar
• Patten SB, Waheed W, Bresee L. A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry. 2012;57(12):717–721.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Pambrun E, Cortaredona S, et al. Antipsychotic prescribing in youths: a french community-based study from 2006 to 2013. Eur Child Adolesc Psychiatry. 2015;24(10):1181–1191.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067–1075.
   PubMed Web of Science ®Google Scholar
• Cicala G, Barbieri MA, Santoro V, et al. Safety and tolerability of antipsychotic drugs in pediatric patients: Data from a 1-Year naturalistic study. Front Psychiatry. 2020;11:152.
   PubMed Web of Science ®Google Scholar
• Krause M, Huhn M, Schneider-Thoma J, et al. Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and Meta-analysis. Eur Neuropsychopharmacol. 2019;29(1):32–45.
   PubMed Web of Science ®Google Scholar
• Martínez-Ortega JM, Funes-Godoy S, Díaz-Atienza F, et al. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry. 2013;22(8):457–479.
   PubMed Web of Science ®Google Scholar
• Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629–635.
   PubMed Web of Science ®Google Scholar
• Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25(5):383–399.
   PubMed Web of Science ®Google Scholar
• Olashore AA, Rukewe A. Polypharmacy among children and adolescents with psychiatric disorders in a mental referral hospital in Botswana. Pharmacotherapy. 2014;34(8):836–844.
   PubMedGoogle Scholar
• Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among medicaid-enrolled youths. JAMA Pediatr. 2015;169(4):e150285:
   PubMed Web of Science ®Google Scholar
• Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state medicaid program. Clin Ther. 2010;32(5):949–959.
   PubMed Web of Science ®Google Scholar
• Kreider AR, Matone M, Bellonci C, et al. Growth in the concurrent use of antipsychotics with other psychotropic medications in medicaid-enrolled children. J Am Acad Child Adolesc Psychiatry. 2014;53(9):960–970.e2.
   PubMed Web of Science ®Google Scholar
• Lohr WD, Creel L, Feygin Y, et al. Psychotropic polypharmacy among children and youth receiving medicaid, 2012-2015. JMCP. 2018;24(8):736–744.
   PubMed Web of Science ®Google Scholar
• Medhekar R, Aparasu R, Bhatara V, et al. Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019;15(4):395–403.
   PubMed Web of Science ®Google Scholar
• Dosreis S, Yoon Y, Rubin DM, et al. Antipsychotic treatment among youth in foster care. Pediatrics. 2011;128(6):e1459-66–e1466.
   PubMed Web of Science ®Google Scholar
• Kowatch RA, Fristad M, Birmaher B, Child Psychiatric Workgroup on Bipolar Disorder, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):213–235.
   PubMed Web of Science ®Google Scholar
• Barbui C, Nosè M, Mazzi MA, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol. 2006;21(6):355–362.
   PubMed Web of Science ®Google Scholar
• Burcu M, Zito JM, Safer DJ, Magder LS, et al. Concomitant use of atypical antipsychotics with other psychotropic medication classes and the risk of type 2 diabetes mellitus. J Am Acad Child Adolesc Psychiatry. 2017;56(8):642–651.
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273–281.
   PubMed Web of Science ®Google Scholar
• Yalçin N, Özdemir N, Çak Esen HT, et al. Potential drug-drug interactions with psychotropic drugs in paediatric inpatients: a cross-sectional study. Int J Clin Pract. 2021;75(6):e14107.
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Lavikainen PT, Korhonen MJ, et al. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care. 2010;16(2):116–122.
   PubMed Web of Science ®Google Scholar
• Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761–766.
   PubMed Web of Science ®Google Scholar
• Saastamoinen LK, Wallin M, Lavikainen P, et al. Treatment duration with selective serotonin reuptake inhibitors among children and adolescents in Finland: a nationwide register study. Eur J Clin Pharmacol. 2012;68(7):1109–1117.
   PubMed Web of Science ®Google Scholar
• Saucedo RS, Liu X, Hincapie-Castillo JM, et al. Prevalence, time trends, and utilization patterns of psychotropic polypharmacy among pediatric medicaid beneficiaries, 1999-2010. Psychiatr Serv. 2018;69(8):919–926.
   PubMed Web of Science ®Google Scholar
• Toteja N, Gallego JA, Saito E, et al. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. Int J Neuropsychopharm. 2014;17(07):1095–1105.
   PubMedGoogle Scholar
• Varimo E, Aronen ET, Mogk H, et al. Antipsychotic treatment duration in children and adolescents: a Register-Based nationwide study. J Child Adolesc Psychopharmacol. 2021;31(6):421–429.
   PubMed Web of Science ®Google Scholar
• Oerbeck B, Overgaard KR, Hjellvik V, et al. The use of antidepressants, antipsychotics, and stimulants in youth residential care. J Child Adolesc Psychopharmacol. 2021;31(5):350–357.
   PubMed Web of Science ®Google Scholar
• Cybulski L, Ashcroft DM, Carr MJ, et al. Temporal trends in annual incidence rates for psychiatric disorders and self-harm among children and adolescents in the UK, 2003-2018. BMC Psychiatry. 2021;21(1):229.
   PubMed Web of Science ®Google Scholar
• Winterstein AG, Soria-Saucedo R, Gerhard T, et al. Differential risk of increasing psychotropic polypharmacy use in children diagnosed with ADHD as preschoolers. J Clin Psychiatry. 2017;78(7):e744–e781.
   PubMed Web of Science ®Google Scholar
• Juul EML, Hjemdal O, Aune T. Prevalence of depressive symptoms among older children and young adolescents: a longitudinal population-based study. Scand J Child Adolesc Psychiatr Psychol. 2021;9:64–72.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, He JP, Brody D, et al. Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics. 2010;125(1):75–81.
   PubMed Web of Science ®Google Scholar
• Rice F, Riglin L, Lomax T, et al. Adolescent and adult differences in major depression symptom profiles. J Affect Disord. 2019;243:175–181.
   PubMed Web of Science ®Google Scholar
• Aman MG, Bukstein OG, Gadow KD, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014;53(1):47–60.e1.
   PubMed Web of Science ®Google Scholar
• Barterian JA, Arnold LE, Brown NV, et al. Clinical implications from the treatment of severe childhood aggression (TOSCA) study: a Re-Analysis and integration of findings. J Am Acad Child Adolesc Psychiatry. 2017;56(12):1026–1033.
   PubMed Web of Science ®Google Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771–791.
   PubMed Web of Science ®Google Scholar
• Lagerberg T, Molero Y, D'Onofrio BM, et al. Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children, adolescents, and young adults: a population-based study in Sweden. Eur Child Adolesc Psychiatry. 2019;28(8):1137–1145.
   PubMed Web of Science ®Google Scholar
• Bushnell GA, Compton SN, Dusetzina SB, et al. Treating pediatric anxiety: Initial use of SSRIs and other antianxiety prescription medications. J Clin Psychiatry. 2018;79(1):16m11415.
   PubMed Web of Science ®Google Scholar
• Gören JL, Parks JJ, Ghinassi FA, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf. 2008;34(10):571–582.
   PubMedGoogle Scholar